COREMINE Oncology enables the analysis of complex cancer-specific mutational profiles (extracted from patient biopsies using next generation sequencing) and will leverage many features of the COREMINE Platform. The tool will help guide the oncologist through the mutational maze, identifying key drivable and druggable mutations, and help the oncologist select the optimal treatment regimen (or clinical trial).

The solution is being developed through a number of active collaborations including the groundbreaking Norwegian Cancer Genomics Consortium’s tumor sequencing program.